{"id":"https://openalex.org/W3149844348","doi":"https://doi.org/10.1002/ardp.202000491","title":"Design, synthesis, docking, ADMET profile, and anticancer evaluations of novel thiazolidine\u20102,4\u2010dione derivatives as VEGFR\u20102 inhibitors","display_name":"Design, synthesis, docking, ADMET profile, and anticancer evaluations of novel thiazolidine\u20102,4\u2010dione derivatives as VEGFR\u20102 inhibitors","publication_year":2021,"publication_date":"2021-03-31","ids":{"openalex":"https://openalex.org/W3149844348","doi":"https://doi.org/10.1002/ardp.202000491","mag":"3149844348","pmid":"https://pubmed.ncbi.nlm.nih.gov/33788290"},"language":"en","primary_location":{"id":"doi:10.1002/ardp.202000491","doi":"https://doi.org/10.1002/ardp.202000491","is_oa":false,"landing_page_url":"https://doi.org/10.1002/ardp.202000491","pdf_url":null,"source":{"id":"https://openalex.org/S174911965","display_name":"Archiv der Pharmazie","issn_l":"0365-6233","issn":["0365-6233","0376-0367","1521-4184"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Archiv der Pharmazie","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5066270766","display_name":"Khaled El\u2010Adl","orcid":"https://orcid.org/0000-0002-8922-9770","observed_orcids":["https://orcid.org/0000-0002-8922-9770"]},"institutions":[{"id":"https://openalex.org/I184834183","display_name":"Al-Azhar University","ror":"https://ror.org/05fnp1145","country_code":"EG","type":"education","lineage":["https://openalex.org/I184834183"]},{"id":"https://openalex.org/I3130228804","display_name":"Heliopolis University","ror":"https://ror.org/02tme6r37","country_code":"EG","type":"education","lineage":["https://openalex.org/I3130228804"]}],"countries":["EG"],"is_corresponding":true,"raw_author_name":"Khaled El\u2010Adl","raw_affiliation_strings":["Pharmaceutical Chemistry Department, Faculty of Pharmacy, Heliopolis University for Sustainable Development, El-Salam City, Cairo, Egypt","Pharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, Cairo, Egypt"],"raw_orcid":"https://orcid.org/0000-0002-8922-9770","affiliations":[{"raw_affiliation_string":"Pharmaceutical Chemistry Department, Faculty of Pharmacy, Heliopolis University for Sustainable Development, El-Salam City, Cairo, Egypt","institution_ids":["https://openalex.org/I3130228804"]},{"raw_affiliation_string":"Pharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, Cairo, Egypt","institution_ids":["https://openalex.org/I184834183"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076753716","display_name":"Helmy M. Sakr","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I184834183","display_name":"Al-Azhar University","ror":"https://ror.org/05fnp1145","country_code":"EG","type":"education","lineage":["https://openalex.org/I184834183"]}],"countries":["EG"],"is_corresponding":false,"raw_author_name":"Helmy Sakr","raw_affiliation_strings":["Pharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, Cairo, Egypt"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, Cairo, Egypt","institution_ids":["https://openalex.org/I184834183"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111179141","display_name":"Sanadelaslam S. A. El\u2010Hddad","orcid":"https://orcid.org/0000-0002-7183-6505","observed_orcids":["https://orcid.org/0000-0002-7183-6505"]},"institutions":[{"id":"https://openalex.org/I184834183","display_name":"Al-Azhar University","ror":"https://ror.org/05fnp1145","country_code":"EG","type":"education","lineage":["https://openalex.org/I184834183"]}],"countries":["EG"],"is_corresponding":false,"raw_author_name":"Sanadelaslam S. A. El\u2010Hddad","raw_affiliation_strings":["Pharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, Cairo, Egypt"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, Cairo, Egypt","institution_ids":["https://openalex.org/I184834183"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010485820","display_name":"Abdel\u2010Ghany A. El\u2010Helby","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I184834183","display_name":"Al-Azhar University","ror":"https://ror.org/05fnp1145","country_code":"EG","type":"education","lineage":["https://openalex.org/I184834183"]}],"countries":["EG"],"is_corresponding":false,"raw_author_name":"Abdel\u2010Ghany A. El\u2010Helby","raw_affiliation_strings":["Pharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, Cairo, Egypt"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, Cairo, Egypt","institution_ids":["https://openalex.org/I184834183"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003933369","display_name":"Mohamed Nasser","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I184834183","display_name":"Al-Azhar University","ror":"https://ror.org/05fnp1145","country_code":"EG","type":"education","lineage":["https://openalex.org/I184834183"]}],"countries":["EG"],"is_corresponding":false,"raw_author_name":"Mohamed Nasser","raw_affiliation_strings":["Pharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, Cairo, Egypt"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, Cairo, Egypt","institution_ids":["https://openalex.org/I184834183"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5031952304","display_name":"Hamada S. Abulkhair","orcid":"https://orcid.org/0000-0001-6479-4573","observed_orcids":["https://orcid.org/0000-0001-6479-4573"]},"institutions":[{"id":"https://openalex.org/I184834183","display_name":"Al-Azhar University","ror":"https://ror.org/05fnp1145","country_code":"EG","type":"education","lineage":["https://openalex.org/I184834183"]},{"id":"https://openalex.org/I4405268078","display_name":"Horus University \u2013 Egypt","ror":"https://ror.org/05qh69251","country_code":"EG","type":"education","lineage":["https://openalex.org/I4405268078"]}],"countries":["EG"],"is_corresponding":false,"raw_author_name":"Hamada S. Abulkhair","raw_affiliation_strings":["Pharmaceutical Chemistry Department, Faculty of Pharmacy, Horus University, New Damietta, Egypt","Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, Cairo, Egypt"],"raw_orcid":"https://orcid.org/0000-0001-6479-4573","affiliations":[{"raw_affiliation_string":"Pharmaceutical Chemistry Department, Faculty of Pharmacy, Horus University, New Damietta, Egypt","institution_ids":["https://openalex.org/I4405268078"]},{"raw_affiliation_string":"Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, Cairo, Egypt","institution_ids":["https://openalex.org/I184834183"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5066270766"],"corresponding_institution_ids":["https://openalex.org/I184834183","https://openalex.org/I3130228804"],"apc_list":{"value":3000,"currency":"USD","value_usd":3000},"apc_paid":null,"fwci":3.7451,"has_fulltext":false,"cited_by_count":49,"citation_normalized_percentile":{"value":0.95121516,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":97,"max":99},"biblio":{"volume":"354","issue":"7","first_page":"e2000491","last_page":"e2000491"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.0015999999595806003,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T14099","display_name":"Synthesis and Characterization of Heterocyclic Compounds","score":0.0012000000569969416,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/thiazolidine-2-4-dione","display_name":"thiazolidine-2,4-dione","score":0.9819999933242798},{"id":"https://openalex.org/keywords/vegfr-2-inhibitors","display_name":"VEGFR-2 inhibitors","score":0.9890000224113464},{"id":"https://openalex.org/keywords/anticancer-agents","display_name":"anticancer agents","score":0.8519999980926514},{"id":"https://openalex.org/keywords/molecular-docking","display_name":"molecular docking","score":0.7360000014305115},{"id":"https://openalex.org/keywords/admet-properties","display_name":"ADMET properties","score":0.8429999947547913},{"id":"https://openalex.org/keywords/cytotoxicity","display_name":"cytotoxicity","score":0.7789999842643738},{"id":"https://openalex.org/keywords/hct116-cells","display_name":"HCT116 cells","score":0.824999988079071},{"id":"https://openalex.org/keywords/hepg2-cells","display_name":"HepG2 cells","score":0.9459999799728394},{"id":"https://openalex.org/keywords/mcf-7-cells","display_name":"MCF-7 cells","score":0.9990000128746033},{"id":"https://openalex.org/keywords/sorafenib","display_name":"sorafenib","score":0.550000011920929},{"id":"https://openalex.org/keywords/drug-design","display_name":"drug design","score":0.43700000643730164},{"id":"https://openalex.org/keywords/intestinal-absorption","display_name":"intestinal absorption","score":0.5989999771118164},{"id":"https://openalex.org/keywords/therapeutic-index","display_name":"therapeutic index","score":0.7710000276565552}],"concepts":[{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.7890491485595703},{"id":"https://openalex.org/C2778695046","wikidata":"https://www.wikidata.org/wiki/Q421136","display_name":"Sorafenib","level":3,"score":0.7550833225250244},{"id":"https://openalex.org/C71240020","wikidata":"https://www.wikidata.org/wiki/Q186011","display_name":"Stereochemistry","level":1,"score":0.6060973405838013},{"id":"https://openalex.org/C2776590680","wikidata":"https://www.wikidata.org/wiki/Q413761","display_name":"Thiazolidine","level":2,"score":0.5874049067497253},{"id":"https://openalex.org/C2777752497","wikidata":"https://www.wikidata.org/wiki/Q286779","display_name":"IC50","level":3,"score":0.5617525577545166},{"id":"https://openalex.org/C41685203","wikidata":"https://www.wikidata.org/wiki/Q1974042","display_name":"Docking (animal)","level":2,"score":0.4927702248096466},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.37624460458755493},{"id":"https://openalex.org/C21951064","wikidata":"https://www.wikidata.org/wiki/Q899212","display_name":"Combinatorial chemistry","level":1,"score":0.3586866557598114},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.3312596082687378},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.19798949360847473},{"id":"https://openalex.org/C2778019345","wikidata":"https://www.wikidata.org/wiki/Q1148337","display_name":"Hepatocellular carcinoma","level":2,"score":0.0},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.0},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.0},{"id":"https://openalex.org/C159110408","wikidata":"https://www.wikidata.org/wiki/Q121176","display_name":"Nursing","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000077157","descriptor_name":"Sorafenib","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D013329","descriptor_name":"Structure-Activity Relationship","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015195","descriptor_name":"Drug Design","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020128","descriptor_name":"Inhibitory Concentration 50","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D040301","descriptor_name":"Vascular Endothelial Growth Factor Receptor-2","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D045162","descriptor_name":"Thiazolidinediones","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":false},{"descriptor_ui":"D045162","descriptor_name":"Thiazolidinediones","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D045162","descriptor_name":"Thiazolidinediones","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D045325","descriptor_name":"HCT116 Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D056945","descriptor_name":"Hep G2 Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061986","descriptor_name":"MCF-7 Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D062105","descriptor_name":"Molecular Docking Simulation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1002/ardp.202000491","doi":"https://doi.org/10.1002/ardp.202000491","is_oa":false,"landing_page_url":"https://doi.org/10.1002/ardp.202000491","pdf_url":null,"source":{"id":"https://openalex.org/S174911965","display_name":"Archiv der Pharmazie","issn_l":"0365-6233","issn":["0365-6233","0376-0367","1521-4184"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Archiv der Pharmazie","raw_type":"journal-article"},{"id":"pmid:33788290","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/33788290","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Archiv der Pharmazie","raw_type":"Comparative Study"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9922999739646912}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":69,"referenced_works":["https://openalex.org/W1416958482","https://openalex.org/W1608710587","https://openalex.org/W1964596754","https://openalex.org/W1967818195","https://openalex.org/W1973035839","https://openalex.org/W1979306439","https://openalex.org/W1988892374","https://openalex.org/W1994701350","https://openalex.org/W1999845081","https://openalex.org/W2003947764","https://openalex.org/W2009867031","https://openalex.org/W2011135513","https://openalex.org/W2028046471","https://openalex.org/W2030537668","https://openalex.org/W2040545329","https://openalex.org/W2063544208","https://openalex.org/W2071635244","https://openalex.org/W2074196937","https://openalex.org/W2083038332","https://openalex.org/W2094465598","https://openalex.org/W2114918609","https://openalex.org/W2120762440","https://openalex.org/W2138787512","https://openalex.org/W2151178480","https://openalex.org/W2161836547","https://openalex.org/W2164460325","https://openalex.org/W2243485378","https://openalex.org/W2340808473","https://openalex.org/W2514195967","https://openalex.org/W2523157690","https://openalex.org/W2538465384","https://openalex.org/W2599722721","https://openalex.org/W2611178855","https://openalex.org/W2744624393","https://openalex.org/W2753778372","https://openalex.org/W2766137786","https://openalex.org/W2769328077","https://openalex.org/W2797570252","https://openalex.org/W2806873888","https://openalex.org/W2889072707","https://openalex.org/W2935502512","https://openalex.org/W2939027651","https://openalex.org/W2967351647","https://openalex.org/W2979647576","https://openalex.org/W2994358408","https://openalex.org/W3005283842","https://openalex.org/W3011682992","https://openalex.org/W3024217372","https://openalex.org/W3024712524","https://openalex.org/W3033659767","https://openalex.org/W3034131973","https://openalex.org/W3034272392","https://openalex.org/W3039947924","https://openalex.org/W3080274977","https://openalex.org/W3081848457","https://openalex.org/W3082029771","https://openalex.org/W3083138156","https://openalex.org/W3083743438","https://openalex.org/W3083774829","https://openalex.org/W3092270666","https://openalex.org/W3093238546","https://openalex.org/W3093317446","https://openalex.org/W3094082197","https://openalex.org/W3096002562","https://openalex.org/W3103854394","https://openalex.org/W3111336007","https://openalex.org/W3113558763","https://openalex.org/W4248107770","https://openalex.org/W4252851641"],"related_works":["https://openalex.org/W3093317446","https://openalex.org/W3034131973","https://openalex.org/W4309438082","https://openalex.org/W4386407945","https://openalex.org/W3039947924","https://openalex.org/W3159182064","https://openalex.org/W3157992644","https://openalex.org/W4390811852","https://openalex.org/W3203819855","https://openalex.org/W2979647576"],"abstract_inverted_index":{"Abstract":[0],"The":[1,73,94,179],"anticancer":[2,177],"activity":[3],"of":[4,31,127,136,193],"novel":[5],"thiazolidine\u20102,4\u2010diones":[6],"was":[7,22],"evaluated":[8],"against":[9,55,92,242,250],"HepG2,":[10,57],"HCT\u2010116,":[11,58],"and":[12,40,59,79,116,165,171,187,196,215,220,232,239],"MCF\u20107":[13,60],"cells.":[14,252],"Among":[15,111],"the":[16,23,28,32,46,52,56,125,137,150,205],"tested":[17,53,95],"cancer":[18,61,243],"cell":[19,62],"lines,":[20,63],"HCT\u2010116":[21],"most":[24,47,74],"sensitive":[25],"one":[26],"to":[27,44,70,83,87,108,167,224],"cytotoxic":[29],"effect":[30],"new":[33,206],"derivatives.":[34],"In":[35],"particular,":[36],"compounds":[37,54,96,113,184,217,230],"18,":[38,114,185,218],"11,":[39,115,186,219],"10":[41,117,188,221,231],"were":[42,81],"found":[43],"be":[45,155],"potent":[48,170],"derivatives":[49,77,145,207],"among":[50],"all":[51],"with":[64,102,175,247],"IC50":[65,103,122,139],"values":[66,104,123],"ranging":[67,105],"from":[68,106],"38.76":[69],"53.99":[71],"\u00b5M.":[72,110],"active":[75],"antiproliferative":[76],"(7\u201314":[78],"15\u201319)":[80],"subjected":[82],"further":[84],"biological":[85],"studies":[86],"evaluate":[88],"their":[89,248],"inhibitory":[90,100],"potentials":[91],"VEGFR\u20102.":[93],"displayed":[97,234],"a":[98,158,198,235],"good\u2010to\u2010medium":[99],"activity,":[101],"0.26":[107],"0.72":[109],"them,":[112],"potently":[118],"inhibited":[119],"VEGFR\u20102":[120,173],"at":[121],"in":[124,202],"range":[126],"0.26\u20130.29":[128],"\u00b5M,":[129],"which":[130],"are":[131,222],"nearly":[132],"three":[133],"times":[134],"that":[135,183],"sorafenib":[138,214],"value":[140],"(0.10":[141],"\u00b5M).":[142],"Although":[143],"our":[144],"showed":[146,182],"lower":[147],"activities":[148],"than":[149],"reference":[151],"drug,":[152],"they":[153],"could":[154,208],"useful":[156],"as":[157,245],"template":[159],"for":[160],"future":[161],"design,":[162],"optimization,":[163],"adaptation,":[164],"investigation":[166],"produce":[168],"more":[169],"selective":[172],"inhibitors":[174],"higher":[176,240],"analogs.":[178],"ADMET":[180],"profile":[181],"do":[189],"not":[190,209],"violate":[191],"any":[192],"Lipinski's":[194],"rules":[195],"have":[197,225],"comparable":[199],"intestinal":[200],"absorptivity":[201],"humans.":[203],"Also,":[204],"inhibit":[210],"cytochrome":[211],"P3A4.":[212],"Unlike":[213],"doxorubicin,":[216],"expected":[223],"prolonged":[226],"dosing":[227],"intervals.":[228],"Moreover,":[229],"18":[233],"wide":[236],"therapeutic":[237],"index":[238],"selectivity":[241],"cells":[244],"compared":[246],"cytotoxicity":[249],"normal":[251]},"counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":15},{"year":2023,"cited_by_count":7},{"year":2022,"cited_by_count":9},{"year":2021,"cited_by_count":8}],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2021-04-13T00:00:00"}